Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horton, E. S.
Right arrow Articles by Whitcomb, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horton, E. S.
Right arrow Articles by Whitcomb, R. W.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 21, Issue 9 1462-1469, Copyright © 1998 by American Diabetes Association

ARTICLES

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group

ES Horton, F Whitehouse, MN Ghazzi, TC Venable and RW Whitcomb
Joslin Diabetes Center, Boston, Massachusetts, USA.

OBJECTIVE: To determine if the combination of troglitazone (a peroxisome proliferator-activated receptor-gamma activator) and sulfonylurea will provide efficacy not attainable by either medication alone. RESEARCH DESIGN AND METHODS: There were 552 patients inadequately controlled on maximum doses of sulfonylurea who participated in a 52-week randomized active-controlled multicenter study. Patients were randomized to micronized glyburide 12 mg q.d. (G12); troglitazone monotherapy 200, 400, or 600 mg q.d. (T200, T400, T600); or combined troglitazone and glyburide q.d. (T200/G12, T400/G12, T600/G12). Efficacy measures included HbA1c, fasting serum glucose (FSG), insulin, and C-peptide. Effects on lipids and safety were also assessed. RESULTS: Patients on T600/G12 had significantly lower mean (+/- SEM) FSG (9.3 +/- 0.4 mmol/l; 167.4 +/- 6.6 mg/dl) compared with control subjects (13.7 +/- 0.4 mmol/l; 246.5 +/- 6.8 mg/dl; P < 0.0001) and significantly lower mean HbA1c (7.79 +/- 0.2 vs. 10.58 +/- 0.18%, P < 0.0001). Significant dose-related decreases were also seen with T200/G12 and T400/G12. Among patients on T600/G12, 60% achieved HbA1c < or =8%, 42% achieved HbA1c < or =7%, and 40% achieved FSG < or =7.8 mmol/l (140 mg/dl). Fasting insulin and C-peptide decreased with all treatments. Overall, triglycerides and free fatty acids decreased, whereas HDL cholesterol increased. LDL cholesterol increased slightly, with no change in apolipoprotein B. Adverse events were similar across treatments. Hypoglycemia occurred in 3% of T600/G 12 patients compared with <1% on G12 or troglitazone monotherapy CONCLUSIONS: Patients with type 2 diabetes inadequately controlled on sulfonylurea can be effectively managed with a combination of troglitazone and sulfonylurea that is safe, well tolerated, and represents a new approach to achieving the glycemic targets recommended by the American Diabetes Association.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Toxicol SciHome page
C. R. Waites, M. A. Dominick, T. P. Sanderson, and B. E. Schilling
Nonclinical Safety Evaluation of Muraglitazar, a Novel PPAR{alpha}/{gamma} Agonist
Toxicol. Sci., November 1, 2007; 100(1): 248 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Prevention of Cardiovascular Disease
Diabetes Care, February 1, 2007; 30(2): 423 - 431.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. J. Abrahamson
A 74-Year-Old Woman With Diabetes
JAMA, January 10, 2007; 297(2): 196 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
B. Kimmel and S. E. Inzucchi
Oral Agents for Type 2 Diabetes: An Update
Clin. Diabetes, April 1, 2005; 23(2): 64 - 76.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
A. Y.Y. Cheng and I. G. Fantus
Oral antihyperglycemic therapy for type 2 diabetes mellitus
Can. Med. Assoc. J., January 18, 2005; 172(2): 213 - 226.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo
Effect of Pioglitazone on Circulating Adipocytokine Levels and Insulin Sensitivity in Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4312 - 4319.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Bays, L. Mandarino, and R. A. DeFronzo
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478.
[Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
R. R. Koski
Oral Antidiabetic Agents: A Comparative Review
Journal of Pharmacy Practice, February 1, 2004; 17(1): 39 - 48.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
V. Fonseca, G. Grunberger, S. Gupta, S. Shen, and J. E. Foley
Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control
Diabetes Care, June 1, 2003; 26(6): 1685 - 1690.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin. Proc.Home page
J. L. Chan and M. J. Abrahamson
Pharmacological Management of Type 2 Diabetes Mellitus: Rationale for Rational Use of Insulin
Mayo Clin. Proc., April 1, 2003; 78(4): 459 - 467.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
S. M. Strowig, M. L. Aviles-Santa, and P. Raskin
Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Troglitazone in Type 2 Diabetes
Diabetes Care, October 1, 2002; 25(10): 1691 - 1698.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Rosenstock, S. G. Shen, M. R. Gatlin, and J. E. Foley
Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes
Diabetes Care, September 1, 2002; 25(9): 1529 - 1533.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. R. Herman, L. A. Dethloff, E. J. McGuire, R. F. Parker, K. M. Walsh, A. W. Gough, H. Masuda, and F. A. de la Iglesia
Rodent Carcinogenicity with the Thiazolidinedione Antidiabetic Agent Troglitazone
Toxicol. Sci., July 1, 2002; 68(1): 226 - 236.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, K. Cusi, L. J. Mandarino, and R. A. DeFronzo
Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2784 - 2791.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. M. Poothullil, N. Mikhail, and S. E. Inzucchi
Drug Therapy for Patients With Type 2 Diabetes
JAMA, April 3, 2002; 287(13): 1645 - 1646.
[Full Text] [PDF]

Home page
 JAMAHome page
S. E. Inzucchi
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
JAMA, January 16, 2002; 287(3): 360 - 372.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Y. Miyazaki, A. Mahankali, M. Matsuda, L. Glass, S. Mahankali, E. Ferrannini, K. Cusi, L. J. Mandarino, and R. A. DeFronzo
Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone
Diabetes Care, April 1, 2001; 24(4): 710 - 719.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring
Pathophysiology and Pharmacological Treatment of Insulin Resistance
Endocr. Rev., December 1, 2000; 21(6): 585 - 618.
[Abstract] [Full Text]

Home page
 Am. J. Clin. Nutr.Home page
S. E Kasim-Karakas, R. U Almario, W. M Mueller, and J. Peerson
Changes in plasma lipoproteins during low-fat, high-carbohydrate diets: effects of energy intake
Am. J. Clinical Nutrition, June 1, 2000; 71(6): 1439 - 1447.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. A. DeFronzo
Pharmacologic Therapy for Type 2 Diabetes Mellitus
Ann Intern Med, August 17, 1999; 131(4): 281 - 303.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
Troglitazone for Type 2 Diabetes
Journal Watch (General), September 11, 1998; 1998(911): 4 - 4.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1998 by the American Diabetes Association.